Lexaria Bioscience Corp. reported earnings results for the second quarter and six months ended February 29, 2024. For the second quarter, the company reported sales was USD 0.145 million compared to USD 0.020025 million a year ago. Net loss was USD 0.649539 million compared to USD 1.3 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.22 a year ago.
For the six months, sales was USD 0.296278 million compared to USD 0.11776 million a year ago. Net loss was USD 1.83 million compared to USD 3.05 million a year ago. Basic loss per share from continuing operations was USD 0.18.